CINECA IRIS Institutional Research Information System

BARAULT, LUDOVIC
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.599
EU - Europa 2.501
AS - Asia 1.877
SA - Sud America 44
OC - Oceania 34
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.084
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.500
CN - Cina 1.166
IT - Italia 876
RU - Federazione Russa 498
SG - Singapore 179
GB - Regno Unito 176
DE - Germania 156
FR - Francia 123
JP - Giappone 114
SE - Svezia 106
IE - Irlanda 88
ES - Italia 82
HK - Hong Kong 80
CA - Canada 73
IN - India 68
TW - Taiwan 61
FI - Finlandia 57
KR - Corea 54
PL - Polonia 47
NL - Olanda 42
UA - Ucraina 40
VN - Vietnam 35
BE - Belgio 32
DK - Danimarca 32
AU - Australia 31
CH - Svizzera 29
ID - Indonesia 28
AT - Austria 26
BR - Brasile 25
MX - Messico 25
GR - Grecia 17
IL - Israele 17
AM - Armenia 16
PT - Portogallo 15
HU - Ungheria 13
NO - Norvegia 10
TR - Turchia 10
BA - Bosnia-Erzegovina 9
RO - Romania 9
AR - Argentina 7
MY - Malesia 7
BN - Brunei Darussalam 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
IR - Iran 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
EG - Egitto 4
JO - Giordania 4
PH - Filippine 4
TN - Tunisia 4
BY - Bielorussia 3
ET - Etiopia 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
TH - Thailandia 3
BD - Bangladesh 2
BG - Bulgaria 2
CL - Cile 2
EC - Ecuador 2
EU - Europa 2
GH - Ghana 2
HR - Croazia 2
KW - Kuwait 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
PE - Perù 2
PK - Pakistan 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
HN - Honduras 1
LK - Sri Lanka 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
Totale 7.084
Salva come PNG Salva come JPEG
Città #
Ann Arbor 378
Beijing 216
Chandler 168
Shanghai 148
Singapore 137
Torino 117
Fairfield 102
Redwood City 102
Santa Clara 101
Guangzhou 93
Dublin 83
Houston 78
Milan 74
Ashburn 69
Woodbridge 69
Cambridge 62
Hangzhou 62
Seattle 62
Nanjing 60
Wilmington 55
Dearborn 52
Nyköping 49
Rome 45
Turin 40
Jacksonville 35
Medford 34
Tokyo 34
Columbus 31
Taipei 31
Changsha 30
Pisa 29
London 27
Villeurbanne 27
New York 25
Wuhan 25
Jakarta 24
Lappeenranta 23
Tianjin 23
Princeton 22
Warsaw 21
Boston 20
Galveston 19
Los Angeles 19
Central 18
Chengdu 18
Shenyang 18
Barcelona 17
Fremont 17
Harbin 17
Helsinki 17
Hong Kong 16
Zhengzhou 15
Boardman 14
Dong Ket 14
Brussels 13
Ottawa 13
Vienna 13
Yerevan 13
Duncan 12
Jinan 12
Moscow 12
Odense 12
Palermo 12
Paris 12
Rotterdam 12
Toronto 12
Central District 11
Chennai 11
Melbourne 11
New Haven 11
Serio 11
Buffalo 10
Chicago 10
Munich 10
Phoenix 10
Rehovot 10
San Diego 10
Bologna 9
Bolzano 9
Chongqing 9
Norwalk 9
San Francisco 9
Simi Valley 9
Trieste 9
Xian 9
Frankfurt am Main 8
Genoa 8
Nanning 8
San Mateo 8
Bari 7
Berlin 7
Bethesda 7
Copenhagen 7
Fuzhou 7
Krakow 7
Lyngby 7
Madrid 7
Manchester 7
Mumbai 7
Oslo 7
Totale 3.546
Salva come PNG Salva come JPEG
Nome #
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.941
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.061
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 590
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 566
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 527
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients 370
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 286
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 228
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 213
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 210
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 178
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 148
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer 120
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 116
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. 114
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 75
Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients 67
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 59
Ras Mutations in Cancer 58
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 56
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients 48
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature 39
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer 28
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models 26
DNA demethylation triggers cell free DNA release in colorectal cancer cells 20
Abstract 6262: Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide 19
Abstract LB058: A transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer 19
null 15
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 15
Abstract B11: Whole-exome sequencing analysis of urine transrenal tumor DNA in metastatic colorectal cancer patients 15
Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth 12
Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation 12
Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer 11
Totale 7.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.555
article - articoli 0
book - libri 0
conference - conferenze 801
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020486 0 0 0 0 0 55 53 73 95 94 72 44
2020/20211.023 47 43 52 75 104 85 93 63 95 130 87 149
2021/20221.135 134 138 120 159 67 56 64 54 71 48 123 101
2022/20231.444 67 72 51 94 68 135 68 89 593 63 71 73
2023/2024886 79 83 66 58 82 69 94 87 27 88 71 82
2024/2025691 43 73 144 122 212 97 0 0 0 0 0 0
Totale 7.262